Skip to main content
Clinical Trials/NCT02698540
NCT02698540
Completed
Not Applicable

A Prospective, Observational Study, of a High Calorie, Higher Protein Peptide Based Oral Nutrition Supplement (ONS) With Medium Chain Triglycerides (MCTs) in a Malnourished Population With GI Tolerance Impairment

Abbott Nutrition23 sites in 1 country95 target enrollmentNovember 28, 2016
ConditionsMalnutrition

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Malnutrition
Sponsor
Abbott Nutrition
Enrollment
95
Locations
23
Primary Endpoint
Study Product Compliance
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose is to observe the compliance to a high-calorie, high protein peptide-based nutritional supplement after 3 months in a malnourished population with impaired gastrointestinal tolerance living in nursing homes and as outpatients.

Registry
clinicaltrials.gov
Start Date
November 28, 2016
End Date
May 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject is considered malnourished, or is at risk for malnutrition based on MUST score ≥
  • Subject is ≥18 years old.
  • Subject has a condition that would benefit from a high calorie, higher protein ONS for GI tolerance impairment (e.g., diarrhea, nausea, vomiting, satiety or bloating).
  • Subject conforms to the requirements set forth on the study product label.
  • Subject is under the care of a health care professional for malnutrition and has recently (within the last 7 days prior to participating in this study) been prescribed 2 servings/day of the study ONS. Subject must have been naïve to ONS for GI tolerance impairment prior to being prescribed the study ONS.

Exclusion Criteria

  • The study physician determines the subject is not fit to participate
  • Subject cannot provide informed consent to participate in the study.
  • Subject cannot safely consume the oral nutritional supplement.
  • Renal or liver failure (GFR\< 60 ml/min or AST/ALTx3 normal) upper limit.
  • Type 1 or type 2 diabetes.

Outcomes

Primary Outcomes

Study Product Compliance

Time Frame: Baseline to Week 12

Subject reported diaries

Secondary Outcomes

  • Nutrition Status(Baseline to Week 12)
  • Quality of Life(Baseline to Week 12)
  • Body Weight(Baseline to Week 12)
  • Gastrointestinal Tolerance(Baseline to Week 12)
  • Body Mass Index(Baseline to Week 12)

Study Sites (23)

Loading locations...

Similar Trials